| Elmwood Hills Healthcare Center Llc | |
| 425 Woodbury-turnersville Road, Blackwood, New Jersey 08012 | |
| (856) 374-6600 | |
| Name | Elmwood Hills Healthcare Center Llc |
|---|---|
| Location | 425 Woodbury-turnersville Road, Blackwood, New Jersey |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 300 |
| Occupancy Rate | 86.5% |
| Medicare ID (CCN) | 315159 |
| Legal Business Name | Elmwood Hills Healthcare Center Llc |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1033547161 |
| Organization Name | ELMWOOD HILLS HEALTHCARE CENTER LLC |
| Address | 425 Woodbury Turnersville Rd, Blackwood, NJ 08012 |
| Phone Number | 856-374-6600 |
News Archive
As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.
European regulators have approved Surefire Medical's Surefire Infusion System, a next generation device for chemo- and radioembolization procedures. The Colorado-based medical device company today announced that it is launching this product in the European market immediately.
Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON (exenatide extended-release for injectable suspension) at the American Diabetes Association's 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.
University of Alabama at Birmingham (UAB) researchers have discovered a key cell-signaling pathway that regulates cell progression and switches on front-to-back body patterning in tadpoles.
The 4th Mobile and Wearable Technology: Healthcare 2014 Conference will be taking place from 3 – 4 April 2014 in Singapore at the Parkroyal Hotel.
› Verified 9 days ago
| NPI Number | 1295721256 |
| Organization Name | CAMDEN COUNTY HEALTH SERVICES CENTER |
| Address | 425 Woodbury Turnersville Rd, Blackwood, NJ 08012 |
| Phone Number | 856-374-6479 |
News Archive
As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.
European regulators have approved Surefire Medical's Surefire Infusion System, a next generation device for chemo- and radioembolization procedures. The Colorado-based medical device company today announced that it is launching this product in the European market immediately.
Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON (exenatide extended-release for injectable suspension) at the American Diabetes Association's 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.
University of Alabama at Birmingham (UAB) researchers have discovered a key cell-signaling pathway that regulates cell progression and switches on front-to-back body patterning in tadpoles.
The 4th Mobile and Wearable Technology: Healthcare 2014 Conference will be taking place from 3 – 4 April 2014 in Singapore at the Parkroyal Hotel.
› Verified 9 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.
European regulators have approved Surefire Medical's Surefire Infusion System, a next generation device for chemo- and radioembolization procedures. The Colorado-based medical device company today announced that it is launching this product in the European market immediately.
Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON (exenatide extended-release for injectable suspension) at the American Diabetes Association's 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.
University of Alabama at Birmingham (UAB) researchers have discovered a key cell-signaling pathway that regulates cell progression and switches on front-to-back body patterning in tadpoles.
The 4th Mobile and Wearable Technology: Healthcare 2014 Conference will be taking place from 3 – 4 April 2014 in Singapore at the Parkroyal Hotel.
› Verified 9 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 19.64 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 10.01 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 53.45 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.56 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.69 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.13 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.59 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 96.38 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 6.98 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 79.36 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.68 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 44.16 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 16.53 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 7.56 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.68 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 73.32 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 80.1 | 82.93 |
News Archive
As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.
European regulators have approved Surefire Medical's Surefire Infusion System, a next generation device for chemo- and radioembolization procedures. The Colorado-based medical device company today announced that it is launching this product in the European market immediately.
Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON (exenatide extended-release for injectable suspension) at the American Diabetes Association's 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.
University of Alabama at Birmingham (UAB) researchers have discovered a key cell-signaling pathway that regulates cell progression and switches on front-to-back body patterning in tadpoles.
The 4th Mobile and Wearable Technology: Healthcare 2014 Conference will be taking place from 3 – 4 April 2014 in Singapore at the Parkroyal Hotel.
› Verified 9 days ago
Elmwood Hills Healthcare Center Llc Location: 425 Woodbury-turnersville Road, Blackwood, New Jersey 08012 Phone: (856) 374-6600 |